Medical practice; ensure that stem cell therapies are used to advance medical treatments and improve patient outcomes in an ethical manner that does not involve stem cells derived from aborted fetuses

Added the list of sponsoring representatives (Newton, Hawkins, Cooper, Au, and Taylor) to the bill header.

Updated the document title from a generic committee offer to a formal 'Committee Substitute' designation.

Removed the mandate that stem cell facilities must be located in Georgia or registered with the FDA.

Added eligibility for stem cell facilities located in any U.S. state or another country, as long as they are registered with the FDA.

The term 'stem cell' was changed to 'human stem cell' in the bill title, summary, and findings to specify the source of the cells.

The definition of 'Wharton's jelly' was updated to include the word 'human' to clarify the tissue source.

A new definition for 'Human stem cell therapy' was added to explicitly state that the term does not include treatments using cells derived from aborted fetuses or embryos.

References to 'stem cells' in the regulatory requirements section were changed to 'human stem cells' to maintain consistency with the new definitions.